Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation

Ain Shams University

Status: Enrolling

Conditions: Liver Transplant

Treatments: Biological: COVID-19 Vaccine

Study type: Observational

Funder types: Other

Identifiers

NCT05051605

RHDIRB2020110301 REC 45

Details and patient eligibility

About

A prospective cohort study to evaluate the response to COVID-19 vaccine in liver transplantation patients.

Full description

fifty living donor liver transplantation recipients during maintenance immunosuppression phase will be vaccinated against COVID-19 followed by assessment of immune response to the vaccine and further investigation of correlation of immune response to genetic polymorphisms of HLA DRB1(rs2647087) gene and IL-18 (rs187238 and rs917997) gene.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age>18
• At least 3 month post transplantation

Exclusion criteria

• pediatric recipients
• Active covid infection at the time of the study
• Pregnancy
• Allergy to any ingredients included in the vaccine
• Lactation in first six month of delivery
• Active Acute cellular rejection proven by liver biopsy
• Acute Febrile state with either leucopenia or leucocytosis
• High dose of corticosteroid at study timing (pulse methyl prednisolone)

Trial design

50 participants in 1 patient group

Vaccinated group

Description:

Fifty living donor liver transplantation recipients on maintenance immunosuppressive regimen who would receive COVID-19 vaccine at least 3 months postoperatively.

Treatment:

Biological: COVID-19 Vaccine